ClinicalTrials.gg
Not yet recruitingNCT07468396Updated Mar 12, 2026

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

A Phase 1 interventional study of GLR2037 in Prostate Cancer, sponsored by Gan & Lee Pharmaceuticals.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 541 studies in Prostatic Neoplasms with a site in China — 280 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
261st of 435
65 · median 100
Started
2026
with 81 others
Phase 1
97 of 541
54 open now
Primary completion
2031-10
later than 336 of 341 live
Registered
474th of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 261st largest by planned enrollment of the 435 interventional ones that give a count, is one of 82 that started in 2026, is one of 97 in phase 1, reaches primary completion later than 336 of the 341 other live ones, and was the 474th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

280 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

275 more — sign in →

All 280 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  1. Male, aged ≥ 18 years.
  2. or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell features.
  3. bone or soft tissue lesions documented by imaging.
  4. Prior surgical or medical castration.
  5. Castrate level of testosterone at screening (≤ 50 ng/dL or 1.73 nmol/L).
  6. Phase Ia and Ib: Prior treatment with at least one novel endocrine therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide, rezlutamide, etc.); patients in the dose-escalation phase of Phase Ia must have received at least one (e.g., docetaxel, cabazitaxel, etc.).
  7. Evidence of disease progression during castration therapy in patients with metastatic prostate cancer at screening.
  8. (ECOG) performance status of 0 to 1.
  9. Adequate organ function meeting protocol-specified criteria.
  10. ≥ 3 months.
  11. Fertile male subjects and their partners must agree to use effective (e.g., condoms) and refrain from donating sperm from the first dose of the study drug until 3 months after the last dose.
  12. Willing to participate in this clinical trial, understand the study procedures, and have signed the form.

Exclusion Criteria:"1. Prior use of AR protein degraders. 2. Use of any other biological and/or immunological anti-tumor therapy (except castration therapy), targeted therapy, estrogen therapy, anti-androgen therapy, or other interventional drug therapy; or receipt of systemic chemotherapy, systemic radiotherapy, or Chinese herbal/patent medicine with anti-tumor indications (as clearly stated in the package insert) within 4 weeks (or 5 half-lives, whichever is shorter) prior to the first dose; or receipt of nitrosoureas, bicalutamide, or nilutamide within 6 weeks (or 5 half-lives, whichever is shorter) prior to the first dose.

3. Subjects who have used bisphosphonates or RANKL inhibitors for the treatment of bone metastases or bone-related diseases within 2 weeks prior to the first dose.

4. Have received systemic therapy within 2 weeks prior to the first dose.

5. Use of strong inhibitors or inducers of CYP2C9 or within 14 days or 5 half-lives (whichever is longer) prior to the first dose.

6. Patients with imaging evidence of brain or central nervous system metastases.

7. Severe bone injury caused by bone metastases of prostate cancer as judged by the investigator.

8. Concurrent uncontrolled hypertension at screening. 9. Presence of active cardiac disease or occurrence of arterial or venous thromboembolism within 6 months prior to the first dose.

10. History of other within 5 years prior to the first dose. 11. Have active (HBsAg positive and HBV-DNA titer ≥ 1×10³ copies/mL), (HCV antibody positive); or severe infections requiring antibiotics, antiviral or antifungal drugs for control.

12.History of immunodeficiency or organ transplantation. 13.Concurrent dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug administration and absorption.

14.Not recovered from adverse events of prior anti-tumor therapy to ≤ Grade 1 at screening.

15.Known allergy to any component or of GLR2037. 16.Subjects who have received palliative radiotherapy or major surgery (Grade 3-4) within 4 weeks prior to the first dose, or have participated in other drug clinical trials within 4 weeks prior to the first dose.

17.Plan to receive any other anti-tumor therapy during the study treatment period other than those specified in the protocol.

18.Any concomitant disease or other condition that, in the judgment of the investigator, poses a serious risk to the safety of the subject or could affect the subject's completion of the study. "

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    GLR2037

    GLR2037 administered one daily(QD) for 28 day cycles.

    Drug: GLR2037

Interventions

  • DrugGLR2037

    GLR2037 administered QD for 28 day cycles.

06

What researchers measure

Primary outcomes

  1. Number of patients with Adverse Events as a measure of safety and tolerability of GLR2037

    Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 6.0), timing, seriousness, and relationship to study drug.

    Time frame: From signing of informed consent to 30 days after last dose (safety follow-up)

  2. Incidence of DLT of GLR2037

    First Cycle Dose limiting toxicities characterized by type, frequency, severity(as graded by NCI CTCAE version 6.0), timing, seriousness, and relationship to study drug

    Time frame: 28 Days

  3. Incidence of laboratory abnormalities as a measure of safety and tolerability of GLR2037

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

    Time frame: From signing of informed consent to 30 days after last dose (safety follow-up)

Secondary outcomes

  1. Assessment of pharmacokinetic (PK) parameter area under the concentration-time curve (AUC).

    Concentration-time curve (AUC) for single dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.

    Time frame: At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037

  2. Assessment of pharmacokinetic parameter maximum concentration (Cmax).

    Maximum concentration (Cmax) for single and multiple dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.

    Time frame: At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037

  3. Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) for single and multiple dose of GLR2037 PK parameters will be assessed when applicable after a single dose and after multiple doses.

    Time frame: At predefined intervals throughout the GLR2037 treatment period, up to last dose of GLR2037

  4. To evaluate the clinical anti-tumor activity of GLR2037 in patients with mCRPC

    Evaluate PSA in patients in both dose groups

    Time frame: 12 Weeks

07

Study locations

1 site
  • No.8 Nanfeng West 1st Street, Huoxian, Tongzhou District
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2031, 66 months later.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 66 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 12, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Oct 30, 2031
CompletionEst.
Apr 30, 2033
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07468396
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Oct 30, 2031 (estimated)
Completion
Apr 30, 2033 (estimated)
Last update
Mar 12, 2026

Study contacts

Yunda Zhuge
Contact
zhugeyunda@ganlee.com
13705398525

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion